As Immunomedics INC (IMMU) Share Value Rose, Venbio Select Advisor LLC Boosted by $55.27 Million Its Stake

February 15, 2018 - By Adrian Mccoy

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It improved, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. 584,308 were accumulated by Ameriprise. Voya Invest Ltd Limited Liability Company owns 50,433 shares or 0% of their US portfolio. The Germany-based Deutsche Bancorp Ag has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). California-based Eam Invsts Lc has invested 0.72% in Immunomedics, Inc. (NASDAQ:IMMU). Ifc Holding Fl has invested 0.04% in Immunomedics, Inc. (NASDAQ:IMMU). California Employees Retirement Systems accumulated 154,647 shares or 0% of the stock. 1.87M were reported by Creative Planning. The Sweden-based Rhenman & Asset Mngmt has invested 0.89% in Immunomedics, Inc. (NASDAQ:IMMU). The New Jersey-based Lord Abbett Co Limited Co has invested 0.05% in Immunomedics, Inc. (NASDAQ:IMMU). Pub Employees Retirement Association Of Colorado holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 29,684 shares. Balyasny Asset Mgmt Limited Liability Company holds 0.01% in Immunomedics, Inc. (NASDAQ:IMMU) or 235,687 shares. 2.86 million are owned by Ecor1 Capital Limited Liability Company. Quantitative Investment Management Limited Com accumulated 25,200 shares or 0% of the stock. Nicholas Investment Partners Ltd Partnership has 334,279 shares for 0.32% of their portfolio. Sg Americas has 26,350 shares for 0% of their portfolio.

Since August 21, 2017, it had 0 buys, and 6 sales for $2.10 million activity. GOLDENBERG CYNTHIA L sold $252,750 worth of Immunomedics, Inc. (NASDAQ:IMMU) on Thursday, August 31.

Venbio Select Advisor Llc increased its stake in Immunomedics Inc (IMMU) by 40.54% based on its latest 2017Q3 regulatory filing with the SEC. Venbio Select Advisor Llc bought 4.25M shares as the company’s stock rose 37.64% with the market. The institutional investor held 14.74M shares of the health care company at the end of 2017Q3, valued at $206.06M, up from 10.49 million at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Immunomedics Inc for a number of months, seems to be bullish on the $2.67 billion market cap company. The stock increased 0.56% or $0.09 during the last trading session, reaching $16.09. About 746,228 shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since February 15, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Venbio Select Advisor Llc, which manages about $380.08 million and $1.29B US Long portfolio, decreased its stake in Immunomedics Inc (Call) (NASDAQ:IMMU) by 9.61 million shares to 875,000 shares, valued at $6.30 million in 2017Q3, according to the filing.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The company was upgraded on Friday, May 6 by Jefferies. The company was maintained on Wednesday, August 16 by Cowen & Co. The firm has “Buy” rating given on Tuesday, September 19 by Jefferies. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. On Tuesday, June 21 the stock rating was downgraded by Wells Fargo to “Market Perform”. Cowen & Co maintained the shares of IMMU in report on Wednesday, December 6 with “Buy” rating. The firm has “Buy” rating given on Thursday, October 6 by Jefferies. On Wednesday, July 29 the stock rating was downgraded by Jefferies to “Hold”. Jefferies maintained the stock with “Buy” rating in Friday, June 9 report. The firm has “Buy” rating given on Monday, October 9 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.